Aceragen announces recommendation of data monitoring committee in terra study

Durham, n.c. and exton, pa., feb. 06, 2023 (globe newswire) -- aceragen, inc. (nasdaq: acgn) a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases, today announced the recommendation of its independent data monitoring committee (dmc) in regard to the on-going terra phase 2 study of acg-701 in patients with melioidosis. the dmc is responsible for providing oversight of safety and efficacy for this study and has recommended the terra study continue without modification.
ACGN Ratings Summary
ACGN Quant Ranking